[Remote] Senior Manager, Clinical Supply Chain at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should have prior experience overseeing a global clinical supply chain, including EU, LATAM, and APAC regions. A background in clinical demand planning, logistics, and product commercialization and distribution is highly preferred. Experience in clinical supply chain management within the pharmaceutical or biotechnology industry is essential, along with strong knowledge of clinical trial operations, global regulations, and compliance requirements such as GCP, GDP, and ICH. Familiarity with global trade compliance and pharmaceutical import/export requirements is also necessary.

Responsibilities

The Senior Manager, Clinical Supply Chain will develop and execute comprehensive clinical supply plans, manage all aspects of clinical trial material logistics including vendor selection and transportation, and implement robust inventory control practices. They will oversee the distribution of investigational products to clinical trial sites, identify and mitigate supply chain risks, and collaborate closely with cross-functional teams. Responsibilities also include ensuring compliance with GCP, GDP, and other regulations, maintaining documentation, assisting with budget development and management for assigned trials, and continuously evaluating and improving supply chain processes for efficiency and cost savings.

Skills

Clinical Supply Chain Management

Demand Forecasting

Inventory Management

Global Logistics

Import/Export

CMC Manufacturing

Quality Assurance

Clinical Operations

CDMO Management

3PL Management

CRO Management

Product Commercialization

Distribution

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free